#United States #Dallas #Caring Cross #Vector BioMed #Boro Dropulic

Boro Dropulic to Share Pivotal Insights at Advanced Therapies Week

As the field of cellular and gene therapies continues to evolve at a rapid pace, industry experts are stepping up to offer their insights on pathways for innovation and accessibility. Boro Dropulic, the Executive Director of Caring Cross and CEO of Vector BioMed, is set to be a key speaker at Advanced Therapies Week (ATW) taking place on January 21-22, 2025, in Dallas, Texas.

Dr. Dropulic will lead three significant sessions, each focusing on different aspects of the future of cell and gene therapies:

1. Plenary Panel: Innovating for the Future of Cell and Gene Therapies
- Date: January 21, 2025
- Time: 9:00 AM - 10:30 AM CST
- Overview: This panel will tackle current challenges and potential solutions that lie ahead for novel cell and gene therapies.

2. Panel Discussion: The CAR-T Story and the Future of Cell Therapies
- Date: January 21, 2025
- Time: 1:15 PM - 2:15 PM CST
- Overview: A deep exploration into the evolution of CAR-T therapies, detailing technological advancements that are reshaping cellular therapy landscapes.

3. Workshop: Transforming Good Science into Sustainable Business
- Date: January 22, 2025
- Time: 8:00 AM - 9:00 AM CST
- Overview: This hands-on workshop will provide actionable strategies for translating scientific breakthroughs into viable commercial products.

Thought Leadership from Dr. Boro Dropulic

Dr. Dropulic is expected to address significant topics such as:

• - High Costs of CAR-T Therapies: Understanding the financial barriers and exploring ways to reduce costs without compromising efficacy.
• - Point-of-Care Manufacturing: Where traditional manufacturing methods can be streamlined for efficiency, allowing therapies to be made closer to where they are needed.
• - Global Access Initiatives: Discussing how to empower low- and middle-income countries (LMICs) to manufacture advanced therapies, thus addressing global healthcare inequalities.

Innovations by Vector BioMed

Vector BioMed is positioning itself as a pioneer in the development of lentiviral vectors, a critical component in many cell and gene therapies. The company aims to disrupt outdated supply chains by:

• - Providing GMP-grade lentiviral vectors at a fraction of current market prices.
• - Focusing on early design refinement to enhance manufacturing efficiency.
• - Planning a series of product launches later in 2025 to solidify its position in the industry.

Caring Cross: Building a Global Network

Through its International Affordable Advanced Therapeutics Manufacturing Network, Caring Cross is working to build robust partnerships aimed at democratizing access to advanced therapies globally. Their initiatives include:

• - Strengthening manufacturing capacity in LMICs.
• - Encouraging collaboration among member organizations for shared success.
• - Advocating for transparent and responsive manufacturing processes.

The goal is to create equitable access to life-saving therapies, ultimately improving healthcare outcomes for diverse populations worldwide.

Engage with the Experts

For those attending ATW, opportunities to connect with Dr. Dropulic and his team await. Interested parties can request meetings through the ATW Event App or reach out via email for discussions on Vector BioMed's lentiviral vector services as well as the initiatives of Caring Cross.

As Dr. Dropulic shares his expertise at this prestigious event, the potential for transformation in the delivery and accessibility of advanced therapies looms on the horizon.